European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free…